Alvotech (ALVO) Stock Insights

ALVO price $4.85 +0.10 +2.11%

Ticker
ALVO
Price
$4.85
Change
+0.10 +2.11%
Market cap ?
$1.73B
P/E ?
-8.31
Forward P/E ?
21.03
Dividend yield ?
0.00%
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stocklytics score
45
Value
43
Quality
39
Growth
52

Stocklytics score rationale: value 43, quality 39, growth 52.

Financials

2019202020212022202320242025
3191800066616000367720008302900091434000489682000586321000

Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of…

Fair value

ALVO fair value $6.12. Price $4.85. Price is 21% below fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 157.44M. Growth 0.22%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 8.70% (beta 0.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 356.82M. Net debt 1.28B. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Compare ALVO

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-11—-0.02—134.22M
2026-08-19-0.11-0.05106.00M103.00M
2026-05-06-0.09-0.07105.90M112.39M
2026-03-18-0.37-0.01173.20M162.19M
2025-11-12-0.02-0.03114.00M116.32M
2025-08-130.14-0.05173.30M117.34M
2025-05-070.35-0.08132.80M95.02M
2025-03-26-0.14-0.03153.38M97.99M
2024-11-13-0.03-0.06103.00M85.00M
2024-08-150.28-0.28198.70M199.00M
2024-05-21-0.89-0.0837.00M84.00M
2024-03-20-1.220.0454.15M93.00M
2023-11-29-0.82-0.0718.00M43.00M
2023-08-30-0.06-0.144.00M42.00M
2023-05-19-0.33—15.86M—
2023-03-01-1.29—23.86M—
2022-11-150.02—19.00M—
2022-09-01-0.54—39.67M—
2022-05-16-0.32—452.00K—
2022-03-30-0.13—34.76M—
2021-11-15-2.60———
2021-08-16-0.01—1.18M—
2021-05-20-4.38—1.18M—
2021-03-31-0.30—16.65M—
2020-09-30-0.17—16.65M—
2020-06-30-0.17—16.65M—
2020-03-31-0.17—16.65M—
2019-12-31-0.22—7.98M—
2019-09-30-0.22—7.98M—
2019-06-30-0.22—7.98M—
2019-03-31-0.22—7.98M—

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
No data yet.

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 73, holders +16 vs prior quarter. Ownership 11.93%.

HolderSharesChangeChange %Value
RUBRIC CAPITAL MANAGEMENT LP15.68M15.68MNew57.85M
MILLENNIUM MANAGEMENT LLC4.26M2.14M+100.87%15.73M
BRACEBRIDGE CAPITAL, LLC4.04M1.33M+49.29%14.90M
VANGUARD CAPITAL MANAGEMENT LLC3.69M279.17K+8.19%13.97M
FARALLON CAPITAL MANAGEMENT, L.L.C.2.86M2.66M+1332.16%10.55M
CITADEL ADVISORS LLC1.73M1.73MNew6.38M
PRICE T ROWE ASSOCIATES INC /MD/1.42M21.29K+1.52%5.23M
BLACKROCK, INC.1.33M82.09K+6.59%4.90M
LITTLEJOHN & CO LLC1.32M00.00%4.87M
VANGUARD FIDUCIARY TRUST CO998.60K24.37K+2.50%3.78M
LEGAL & GENERAL GROUP PLC696.05K191.59K+37.98%2.65M
MORGAN STANLEY670.04K426.76K+175.42%2.47M
ROYCE & ASSOCIATES LP558.14K558.14KNew2.06M
JPMORGAN CHASE & CO529.69K25.49K+5.06%1.97M
SONA ASSET MANAGEMENT (US) LLC360.00K360.00KNew1.33M
GEODE CAPITAL MANAGEMENT, LLC297.26K-26.94K-8.31%1.10M
UBS GROUP AG253.48K-68.67K-21.32%935.35K
HUDSON BAY CAPITAL MANAGEMENT LP238.11K238.11KNew878.62K
VANGUARD ASSET MANAGEMENT, LTD151.94K00.00%575.07K
LIGHTHOUSE INVESTMENT PARTNERS, LLC125.00K125.00KNew461.25K
ULLAND INVESTMENT ADVISORS, LLC109.50K11.40K+11.62%404.00K
OAKTREE CAPITAL MANAGEMENT LP97.98K-142.06K-59.18%361.55K
INVESCO LTD.90.48K12.03K+15.34%333.86K
SAVANT CAPITAL, LLC83.73K5.91K+7.60%308.97K
STIFEL FINANCIAL CORP78.95K36.38K+85.44%291.33K

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Alvotech (ALVO) Stock Insights

ALVO$4.85+0.10 +2.11%

$1.73B

Market Cap

-8.31

P/E

21.03

Forward P/E

45

Score

Price History